Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

World Health Organization, Solid Tumors, Cancer Management +17

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

Richard Simon, Larry Rubinstein, Susan G. Arbuck et al. · JNCI Journal of the National Cancer Institute · 1997 · 632 citations · Full text

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

Robert W. Wilkinson, Rajesh Odedra, Simon P. Heaton et al. · Clinical Cancer Research · 2007 · 355 citations · Full text

Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability.

Takahide Ota, Shiho Suto, Hiroshi Katayama et al. · PubMed · 2002 · 293 citations

Histone H3, Genetics, Molecular Genetics +22

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

Jing Yang, Takayuki Ikezoe, Chie Nishioka et al. · Blood · 2007 · 284 citations · Full text